Demo Data from EDBT 2026 / reviewers in the wild / expert
Jennifer Deng
dblp:351/9831
· DBLP profile ↗
2ranked-venue papers
0as first author
2since 2021 · last 2023
0009-0008-5239-5653ORCID · corroborated
Domains — the database's venue-derived domains; a paper can count in several
Artificial intelligence and machine learning · 1 · 1 since 2021Databases, data management, data science and information retrieval · 1 · 1 since 2021
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
2 papers |
Bioinformatics and computational biology · 87% Medical and health informatics · 13% | |
| Artificial intelligence
1 paper |
Information extraction and text analysis · 100% | |
| Databases, data mining, and information retrieval
1 paper |
Data mining · 100% |
Topics — the 5 heaviest of 6, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Natural language and speech › Information extraction and text analysis › entity linking
biomedical entity linking |
0.7 | 1 | 2023 | A Comprehensive Evaluation of Biomedical Entity Linking Models · EMNLP 2023 |
Natural language and speech › Information extraction and text analysis
entity linking |
0.7 | 1 | 2023 | A Comprehensive Evaluation of Biomedical Entity Linking Models · EMNLP 2023 |
Bioinformatics and computational biology › biomedical text mining
biomedical entity linking |
0.7 | 1 | 2023 | A Comprehensive Evaluation of Biomedical Entity Linking Models · EMNLP 2023 |
Bioinformatics and computational biology › drug discovery
drug repurposing |
0.7 | 1 | 2023 | BioSift: A Dataset for Filtering Biomedical Abstracts for Drug Repurposing and Clinical Meta-Analysis · SIGIR 2023 |
Data mining › text mining
text classification |
0.7 | 1 | 2023 | BioSift: A Dataset for Filtering Biomedical Abstracts for Drug Repurposing and Clinical Meta-Analysis · SIGIR 2023 |
Methods — techniques the papers use, named apart from their topics
weak supervision · 1.3full supervision · 1.3active learning · 1.3
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2023 | A Comprehensive Evaluation of Biomedical Entity Linking ModelsabstractBiomedical entity linking (BioEL) is the process of connecting entities referenced in documents to entries in biomedical databases such as the Unified Medical Language System (UMLS) or Medical Subject Headings (MeSH). The study objective was to comprehensively evaluate nine recent state-of-the-art biomedical entity linking models under a unified framework. We compare these models along axes of (1) accuracy, (2) speed, (3) ease of use, (4) generalization, and (5) adaptability to new ontologies and datasets. We additionally quantify the impact of various preprocessing choices such as abbreviation detection. Systematic evaluation reveals several notable gaps in current methods. In particular, current methods struggle to correctly link genes and proteins and often have difficulty effectively incorporating context into linking decisions. To expedite future development and baseline testing, we release our unified evaluation framework and all included models on GitHub at https://github.com/davidkartchner/biomedical-entity-linking. David Kartchner, Jennifer Deng, Shubham Lohiya, Tejasri Kopparthi, Prasanth Bathala, Daniel Domingo-Fernández, Cassie S. Mitchell |
EMNLP | 2 |
| 2023 | BioSift: A Dataset for Filtering Biomedical Abstracts for Drug Repurposing and Clinical Meta-AnalysisabstractThis work presents a new, original document classification dataset, BioSift, to expedite the initial selection and labeling of studies for drug repurposing. The dataset consists of 10,000 human-annotated abstracts from scientific articles in PubMed. Each abstract is labeled with up to eight attributes necessary to perform meta-analysis utilizing the popular patient-intervention-comparator-outcome (PICO) method: has human subjects, is clinical trial/cohort, has population size, has target disease, has study drug, has comparator group, has a quantitative outcome, and an "aggregate" label. Each abstract was annotated by 3 different annotators (i.e., biomedical students) and randomly sampled abstracts were reviewed by senior annotators to ensure quality. Data statistics such as reviewer agreement, label co-occurrence, and confidence are shown. Robust benchmark results illustrate neither PubMed advanced filters nor state-of-the-art document classification schemes (e.g., active learning, weak supervision, full supervision) can efficiently replace human annotation. In short, BioSift is a pivotal but challenging document classification task to expedite drug repurposing. The full annotated dataset is publicly available and enables research development of algorithms for document classification that enhance drug repurposing. David Kartchner, Irfan Al-Hussaini, Haydn Turner, Jennifer Deng, Shubham Lohiya, Prasanth Bathala, Cassie S. Mitchell |
SIGIR | 4 |